Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
With the sustained protection of HEMLIBRA,1,2 life can be beautifully spontaneous
Treated annualised bleed rate (ABR) was 1.5 for HEMLIBRA every week (1.5 mg/kg/QW) and 1.3 for HEMLIBRA every 2 weeks (3.0 mg/kg/Q2W) vs. 38.2 for episodic FVIII. Sustained mean trough plasma concentrations of HEMLIBRA were achieved across all doses (open-label studies).1,2
HEMLIBRA delivers sustained protection,1,2 with a half-life of weeks, not hours
HEMLIBRA
protects
patients, with 82% maintaining zero treated bleeds after 144 weeks (n=140/170).3
HEMLIBRA
supports
patients, with many no longer experiencing joint pain, swelling, painful movements or difficulty walking.4
HEMLIBRA
is preferred
by patients, with >90% favouring it over their prior FVIII prophylaxis (n=55/60).5
Experience with HEMLIBRA is growing
Learn about real-world effectiveness of HEMLIBRA, as evaluated by the UK Haemophilia Centre Doctors’ Organisation (UKHCDO).
Watch experts discuss HEMLIBRA at the latest global congresses and symposia.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. As HEMLIBRA® is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.
For full details please refer to:
Great Britain HEMLIBRA® Summary of Product Characteristics
Northern Ireland HEMLIBRA® Summary of Product Characteristics
ABR, annualised bleed rate; FVIII, Factor VIII; MOA, mechanism of action; QW, every week; Q2W, every 2 weeks; UKHCDO, UK Haemophilia Centre Doctors’ Organisation.
References:
- Mahlangu J et al. N Engl J Med 2018;379:811-22.
- Oldenburg J et al. N Engl J Med 2017;377:809-18.
- Callaghan M et al. Blood 2021;137:2231–42.
- von Mackensen S et al. Haemophilia 2020;26:1019–30.
- Kempton C et al. Haemophilia 2021;27:221–28.
M-GB-00006225
Date of preparation: March 2022
